Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.Peer-Reviewed Original ResearchMeSH KeywordsAgedBenzhydryl CompoundsBiomarkersClinical Trials, Phase IV as TopicFatty AcidsFemaleGlucosidesHeart FailureHumansMaleMetabolomicsMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsStroke VolumeTreatment OutcomeVentricular Function, LeftConceptsHeart failureBranched-chain amino acidsEnd pointsEjection fractionLeft ventricular ejection fraction spectrumMetabolite factorsMetabolic effectsSpectrum of ejection fractionSGLT2 inhibitor dapagliflozinReduced ejection fractionHF-related outcomesEjection fraction spectrumMechanisms of benefitDEFINE-HFAcid metabolismInhibitor dapagliflozinOverall cohortMetabolomic profilesLVEFMetabolic signaturesRandomized trialsDapagliflozinHF subtypesFatty acid metabolismAmino acid metabolismProjected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply